SEC Form 3

FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## **INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL

3235-0104 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Medici Frank	edici Frank (Month/Day/Year) 07/30/2014 et) (First) (Middle)		3. Issuer Name <b>and</b> Ticker or Trading Symbol <u>HEALTHEQUITY INC</u> [ HQY ]				
(Last) (First) (Middle) 475 STEAMBOAT ROAD			4. Relationship of Reporting Per (Check all applicable) X Director Officer (give title	son(s) to Issuer 10% Owne Other (spec	r (Mor	<ul><li>5. If Amendment, Date of Original Filed (Month/Day/Year)</li><li>6. Individual or Joint/Group Filing (Check</li></ul>	
(Street) GREENWICH CT 06830			below)	below)	Appl X		y One Reporting Person y More than One erson
(City) (State) (Zip)							
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownershi Form: Direc or Indirect ( (Instr. 5)	t (D)   (Instr	Nature of Indirect Beneficial Ownership nstr. 5)		
Table II - Derivative Securities Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	tive or Indirect	
Series C Preferred Stock	(1)	(1)	Common Stock	7,157,346	(1)	I	See footnote <sup>(5)</sup>
Series D-1 Preferred Stock	(1)	(1)	Common Stock	5,152,986	(1)	I	See footnote <sup>(5)</sup>
Series D-2 Preferred Stock	(1)	(1)	Common Stock	909,090	(1)	I	See footnote <sup>(5)</sup>
Series D-3 Preferred Stock	(1)	(1)	Common Stock	825,868	(1)	Ι	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	03/26/2019	Common Stock	30,000	1.1	Ι	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	01/07/2017	Common Stock	30,000	1.1	Ι	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	01/07/2018	Common Stock	30,000	1.1	I	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	04/15/2020	Common Stock	30,000	1.1	Ι	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	04/29/2021	Common Stock	30,000	1.8	Ι	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	04/26/2022	Common Stock	30,000	2.25	I	See footnote <sup>(5)</sup>
Stock Option (right to buy)	(2)	05/09/2023	Common Stock	30,000	2.5	I	See footnote <sup>(5)</sup>
Warrant (right to buy)	(3)	05/21/2017	Common Stock	813,713	0.01	Ι	See footnote <sup>(5)</sup>
Warrant (right to buy)	(3)	02/07/2018	Common Stock	143,147	1.68	Ι	See footnote <sup>(5)</sup>
Warrant (right to buy)	(4)	08/11/2016	Common Stock	182,000	0.01	Ι	See footnote <sup>(5)</sup>

Explanation of Responses:

1. The reported securities automatically will convert into shares of common stock on the business day immediately prior to the closing date of the initial public offering of HealthEquity, Inc.

2. The option is immediately exercisable.

3. The warrant is immediately exercisable.

4. The warrant is immediately exercisable and will terminate upon the earlier of (i) August 11, 2016 and (ii) the closing of the initial public offering of HealthEquity, Inc.

5. See Exhibit 99.1 for the text of footnote (5).

## **Remarks:**

Exhibit List: Exhibit 99.1 - Explanation of Responses

/s/ Frank Medici

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

07/28/2014

(5) All securities are held of record by Berkley Capital Investors, L.P., a Delaware limited partnership ("Berkley Investors"). Berkley Capital, LLC, a Delaware limited liability company ("Berkley Capital") is the general partner of Berkley Investors. The reporting person is an officer of Berkley Capital. The reporting person disclaims beneficial ownership of the securities held by Berkley Investors and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for Section 16 or any other purposes.